Leukemia, Myeloid, Chronic Clinical Trial
Official title:
Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™
Verified date | September 2012 |
Source | Agenus, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a Phase II, exploratory, open-label study of the investigational product AG-858, in
patients who are cytogenetically positive after treatment with Gleevec.
The trial will consist of three independent Phase II evaluations of patient groups according
to their cytogenetic status as defined in the eligibility criteria (Eligibility Criteria 4a,
4b, and 4c).
Status | Terminated |
Enrollment | 40 |
Est. completion date | April 2006 |
Est. primary completion date | April 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must be Philadelphia chromosome positive chronic myelogenous leukemia in first chronic phase - Must have a complete hematologic response - Must have received Gleevec™, IFN-a, cytarabine, busulfan, hydroxyurea, Homoharringtonine (HHT) or any combination thereof as long as the combination has been discontinued and the dosing of Gleevec™ has been stable for 6 months or greater - Must have one of the following cytogenetic statuses: (A) Less than a CCR after receiving Gleevec™ for at least one year at a minimum dose of 400 mg/day. A stable dose of Gleevec™ must have been maintained for the last six months prior to eligibility testing OR (B) Stable cytogenetic status without CCR (no cytogenic response or progression) in three consecutive determinations over six months while on a stable dose of Gleevec™ (at a minimum of 400mg/day) for at least 6 months OR (C) Cytogenetic progression while on a stable dose of Gleevec™ (at a minimum dose of 400mg/day)for at least 2 consecutive evaluations at least one month apart - ECOG performance score of 0 or 1 - Must be at least 18 years old - Not pregnant or breastfeeding and agree to use contraception during the course of the study - No prior allogeneic bone marrow transplant or be candidates for curative BMT - No immunodeficiency or other serious illness - No current use of immunosuppressive medications - No other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Agenus, Inc. |
United States, United Kingdom,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Completed |
NCT00186342 -
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
|
N/A | |
Completed |
NCT00759837 -
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
|
Phase 1 | |
Completed |
NCT00538109 -
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
N/A | |
Completed |
NCT00040105 -
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
|
Phase 1 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Recruiting |
NCT01015742 -
Unrelated Double Umbilical Cord Blood Units Transplantation
|
Phase 2/Phase 3 | |
Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
Completed |
NCT00246662 -
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT00264160 -
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
|
Phase 2/Phase 3 | |
Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT00538447 -
Prospective Database for Chronic Myelogenous Leukemia
|
N/A | |
Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
Completed |
NCT00034684 -
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04260022 -
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
|
Phase 1 | |
Terminated |
NCT00167180 -
Post Transplant Donor Lymphocyte Infusion
|
Phase 2 | |
Terminated |
NCT00449761 -
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
|
Phase 2 | |
Completed |
NCT00455221 -
Safety Assessment of a Multipeptide-gene Vaccine in CML
|
Phase 1 | |
Completed |
NCT00298987 -
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
|
Phase 2 | |
Completed |
NCT00763763 -
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
|
Phase 2 |